AGIOS PHARMACEUTICALS, INC. (AGIO) research
AGIOS PHARMACEUTICALS, INC.- Sector
- Biotechnology
- Last price
- $31.25
- As of
Kresmion compiles this page from AGIO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
AGIOS PHARMACEUTICALS, INC. (AGIO): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.
As of . Source: SEC EDGAR filings for AGIO. Method and limitations.
Share the AGIO intelligence card
See the full AGIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for AGIO on one page. Preview it with sample data, then open it live with a free account.
Preview the AGIO dossierActive signals for AGIO
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 58% of AGIO (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 56% of AGIO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +249% to AGIO (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +3345% to AGIO (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +113% to AGIO (2026Q2)
FREE, NO ACCOUNT
Every signal on AGIO, as it fires
You are seeing 5 of 11 signals recorded on AGIO since 2026-06-21.
The five above all landed on 2026-08-16. The other 6 were recorded on 2 other days. 8 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in AGIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 00847X104 · 2026Q2 | $115.3M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 00847X104 · 2026Q2 | $27.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00847X104 · 2026Q2 | $19.9M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 00847X104 · 2026Q2 | $18.8M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, AGIO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
AGIO against its peers
AGIO's operating margin of -873.9% ranks in the 14th percentile of 17 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | AGIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 54.0M USD | 106M USD | 25 | 17 |
| Operating margin | -873.9% | -113.7% | 14 | 17 |
| Net margin | -764.0% | -91.5% | 18 | 18 |
| Return on equity | -34.6% | -47.4% | 53 | 19 |
| P / E | n/a | 7.6x | n/a | 5 |
Peers (22): RXRX, BHVN, PVLA, LKFT, URGN, ZYME, VCEL, MESO, ABSI, VIR, AUPH, BCRX, SRPT, XNCR, ZBIO, SEPN, NVAX, PHVS, MLYS, ADMA, NTLA, VRDN. Left out: BRVE (no annual filing), GENB (no annual filing), ADRX (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (AGIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow AGIO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to AGIO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.